Side effects not a major problem for new class of breast cancer drugs

[News]

A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most...

More... (http://www.medicalnewstoday.com/releases/318449.php)